,
Goutzamanis, Stelliana http://orcid.org/0000-0002-9302-2430
Doyle, Joseph S.
Thompson, Alexander
Dietze, Paul
Hellard, Margaret
Higgs, Peter
Funding for this research was provided by:
Gilead Sciences
Article History
Received: 4 August 2017
Accepted: 21 March 2018
First Online: 2 April 2018
Ethics approval and consent to participate
: All TAP participants provided informed written consent and extra informed verbal consent to participate in the qualitative interview. Ethics approval was received by the Monash University Human Research Ethics Committee.
: Participants provided informed consent for publications of findings.
: J Doyle has received research funding from Gilead Sciences, GSK and Abbvie Inc. A Thompson has served as a consultant for Gilead Sciences, Merck & Co, Abbvie Inc., Bristol-Myers Squibb and Roche Diagnostics, a speaker for Bristol-Myers Squibb and has received research funding from Gilead Sciences, Abbvie Inc., Merck & Co and Bristol-Myers Squibb. P Dietze has received research funding from Gilead Sciences and Reckitt Benckiser. M Hellard has received investigator initiated research funding from Gilead Sciences, GSK and Abbvie Inc. P Higgs has received research funding from Gilead Sciences.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.